樂
樂觀
樂觀 · 25%HKPD
$1.53
情境價格
$1.450
+0.096 (+6.62%)收盤時
Loading chart…
- 最高
- 1.600
- 開盤
- 1.420
- 成交量加權均價
- 1.47
- 成交量
- 48.81K
- 市值
- —
- 最低
- 1.360
- 成交金額
- 71.76K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services.
AI 分析 of Cellyan Biotechnology Co Ltd (HKPD)
賣出Given the current price of 1.45, the RSI at 25.446 indicates that the stock is oversold, but the significant year-to-date decline of 91.01% and negative earnings trends suggest that this is not a good buy right now. The main risk is the compliance warning from Nasdaq, which could further impact investor confidence and stock performance.
估值指標
Cellyan Biotechnology Co Ltd（HKPD）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。
Alphio AI 對 HKPD 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
7.007-17NASDAQ.COMCellyan Biotechnology Receives Nasdaq Compliance Extension
8.507-16seekingalphaCellyan Biotechnology Secures Nasdaq Compliance Extension
- 8.501-16seekingalpha
Cellyan Biotechnology (HKPD) Receives Nasdaq Warning for Non-Compliance with $1 Minimum Bid Price
7.001-16GlobenewswireCellyan Biotechnology Receives Nasdaq Notification for Share Price Below $1
- 9.012-17Globenewswire
HKPD Approves Major Capital Restructuring at 2025 Annual Meeting
HKPD 常見問題 —— 由 Alphio AI 解答
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services. It operates in the Healthcare sector.
Given the current price of 1.45, the RSI at 25.446 indicates that the stock is oversold, but the significant year-to-date decline of 91.01% and negative earnings trends suggest that this is not a good buy right now. The main risk is the compliance warning from Nasdaq, which could further impact investor confidence and stock performance.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。